Estrogen triggers transactivation coupled estrogen receptor a (ERa) proteolysis, but mechanisms thereof remain obscure. Present data link estrogen:ERa-driven transcription with cell cycle progression. Although liganded ERa induces many genes within 1-4 h, gene activation after 6 h is thought to be indirect. Here, we identify SKP2 as a late-acting coactivator that drives ERa targets to promote G1-to-S progression. Data support a model in which estrogen-activated cyclin E-CDK2 binds and phosphorylates ERaS341, to prime ERa-SCF SKP2 binding via SKP2-L 248 QTLL 252 in late G1. SKP2 activates ERa ubiquitylation and proteolysis. Putative late ERa targets were identified by expression profiling. SKP2 knockdown attenuated E2F-1 and BLM induction. SKP2 overexpression, but not coactivator motif mutant SKP2-L 248 QTAA 252, enhanced estrogen-induced E2F-1 and BLM expression. SKP2 knockdown impaired estrogen-stimulated ERa, SKP2, SRC3 and RNA polymerase II recruitment to E2F-1 and BLM promoters. This work not only identifies these late-activated genes as bona fide ERa targets but describes a novel mechanism for their periodic activation. SKP2 serves as dual ERa E3 ligase/coactivator for late-activated target genes, revealing a novel mechanism whereby ERa/SCF SKP2 transactivation of E2F-1 feeds forward to drive G1-to-S.
INTRODUCTION
Estrogen acts as a cell-type-dependent mitogen by rapid cross talk, activating Src and mitogen-activated protein kinase (MAPK) signaling, 1 and by triggering estrogen receptor a (ERa) to bind coactivators/chromatin remodeling factors to induce mitogenic target gene transcription 2, 3 and cell cycle progression. 4 Most ERa coactivators contain one or more Leu-XX-Leu-Leu (LXXLL) motifs, which bind directly to ERa helix-12. 5 Ligand binding to many nuclear hormone receptors, including estrogen, 6, 7 thyroid hormone 8 and progesterone 9 receptors activates receptor proteolysis. Mechanisms governing ligandactivated ERa proteolysis are not fully elucidated and may be linked to target gene expression. Coactivator binding may regulate both transcriptional activity and ligand-mediated ERa proteolysis. In some 10, 11 but not all models, 12, 13 proteasome inhibition decreases estrogen-ERa transcriptional activity despite an increase in ERa abundance. Proteasome inhibitors reduce ERa transcription activity and ultimately re-localize receptor to nucleosomes. 11 Thus, for a subset of ERa-driven genes, ERa ubiquitylation and transcriptional activity may be linked. Indeed, ERa proteolysis after promoter firing may allow promoter reloading and globally regulate both ERa abundance and overall activity. Constitutive ERa activation could potentially reduce ERa levels via ERa proteolysis.
Signaling pathways that activate many transcription factors (TFs), including c-Jun and c-Myc, also trigger their ubiquitindependent degradation, 14 thereby limiting transcriptional activity. TF ubiquitylation may affect coactivator/repressor binding with coactivators enhancing TF ubiquitylation.
14 Ubiquitin is first linked to an ubiquitin-activating enzyme, transferred to an ubiquitinconjugating enzyme (Ubc), then an ubiquitin ligase, or E3, facilitates substrate ubiquitylation. Substrate polyubiquitylation signals its 26S proteasomal degradation. 15 Certain ERa coactivators have dual roles as E3 ligases. These include E6-associated protein (E6-AP) 16 and murine double minute 2 (MDM2). 17 For many E3 ligases, substrate recognition is regulated by its phosphorylation. Thus, ERa phosphorylation by different signaling pathways could theoretically promote recruitment of different dual role coactivators, thereby changing both the profiles of ERa targets expressed and ERa proteolysis rates.
To elucidate how ERa proteolysis may be linked to target gene expression, we investigated an SCF E3 ligase as putative ERa coactivator. SCF complexes comprise a large E3 family that include SKP1, CUL1 (mammalian homolog of yeast Cdc53), an F-box protein, and RBX1/RBX2 (ROC1/ROC2). Over 70 human F-box proteins bind appropriately phosphorylated substrates to recruit them to the SCF. 18 An in silico search revealed several F box proteins contain the ERa coactivator signature motif, LXXLL. One of these, SKP2, mediates degradation of several cell cycle proteins.
The present study links ERa transcriptional activity with the cell cycle machinery. Cell cycle progression is governed by cyclindependent kinases (CDKs). In G1, cyclin D-bound CDK activation precedes cyclin E-CDK2 activation and both coordinately phosphorylate the retinoblastoma protein to activate the E2F-1 TF. 19 E2F-1, in turn, transactivates genes required for S-phase progression. Many cyclin E-CDK2 substrates promote S and G2/ M progression. 19, 20 Here, we identify SCF SKP2 as an E3 ligase involved in estrogenactivated ERa degradation and present a model in which cyclin 1 Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA; E-CDK2 binds and phosphorylates ERaS341 to prime ERa interaction with SKP2 in late G1. Microarray analysis identified putative late upregulated ERa-target genes. Two late-G1 ERa targets, E2F-1 and BLM, are co-regulated by SKP2, supporting the notion that SCF SKP2 has a dual role as E3 ligase and coactivator for ERa. Data also reveal a feed forward loop whereby estrogen stimulates SKP2-dependent ERa transactivation of E2F-1, which in turn induces further cyclin E and SKP2 expression to drive S-phase entry.
RESULTS

SCF
SKP2 complex binding to ERa is estrogen dependent
As noted above, several F-box proteins contain the signature steroid hormone coactivator motif LXXLL. To test if SCFs regulate ERa proteolysis, a dominant-negative CUL1 (Cul1 DN ) was overexpressed in MCF-7 to disrupt SCF function. Cul1 DN did not affect ERa levels in the absence of 17-b-estradiol (E2) but reproducibly attenuated E2-triggered ERa degradation ( Figure 1a ). As CUL1 is required for SCF-mediated proteolysis, this supported further analysis of LXXLL-bearing F-box proteins as regulators of ERa proteolysis (see below).
The F-box protein, SKP2, localizes to the nucleus 21 and contains two LXXLL motifs. As such, it could participate in ligand-activated nuclear ERa proteolysis. 11 Immunoprecipitates of cellular SCF SKP2 components, SKP1, SKP2, CUL1 and RBX1 from two different ERapositive lines, MCF-7 and ZR-75-1 all contained associated ERa ( Figure 1b) . None of these proteins bound nonspecific antibody. Immunodepletion of SKP2 followed by ERa IP suggests only a minority of ERa is detected in SKP2 complexes ( Figure 1b , lower panel).
In both MCF-7 and ZR-75-1, ERa-SKP2 interaction was not detected in E2-deprived cells but increased rapidly after E2 addition ( Figure 1c , see also Figures 4d and f). Pre-treatment with E2 antagonist, 4-hydroxytamoxifen prevented E2-stimulated SKP2-ERa binding (Figure 1c) . That ERa-SKP2 binding is estrogendependent is not surprising as the coactivator LXXLL-binding surface in ERa is only exposed in the presence of estrogenic ligand and is not available in unliganded or tamoxifen-bound ERa. Although a 1-h pre-treatment with proteasome inhibitor, Z-LeuLeu-Leu-CHO (MG-132) was too short to significantly affect ERa or SKP2 levels, E2-stimulated ERa-SKP2 complexes were stabilized (Figure 1d ), compatible with a transient ERa-SKP2 interaction preceding ERa proteolysis in both lines.
SKP2 mediates estrogen-dependent ERa ubiquitylation and degradation in cells and in vitro
To further test if SCF SKP2 mediates ERa degradation, a stable SKP2-overexpressing MCF-7 line was constructed (Figure 2a) . Cycloheximide (CHX) chase showed high ERa stability in the absence of E2 both without and with SKP2 overexpression (t 1/2 424 h). E2 driven ERa proteolysis increased with SKP2 overexpression, with the ERa t 1/2 falling from 6 to 4.5 h ( Figure 2a) ; thus SKP2 is rate limiting for E2-dependent ERa degradation.
Two different SKP2 ShRNA lentiviri (ShSKP2-1 and ShSKP2-2) were used to stably knockdown SKP2 in MCF-7. E2-deprived ShSKP2 and control MCF-7 showed a similar ERa t 1/2 . In contrast, after E2 stimulation in both MCF-7 shSKP2 lines, the ERa t 1/2 was increased nearly twofold (ERa t 1/2 ¼ 11 h) compared with scramble Sh-controls (ERa t 1/2 ¼ 6 h; representative data for ShSKP2-1 and ShSKP2-2, Figure 2b ). This and the finding that ERa and SKP2 fail to interact in the absence of E2 (Figure 1c) (Figure 3a) . Thus, the L 248 QTLL 252 is important for SKP2-ERa binding. Crystal structure analysis reveals that SKP2 binds SKP1 through L 114 PELL 118 F-box, 22 thus simultaneous SKP2 interaction with both SKP1 and ERa as its F-box substrate would require use of the L 248 QTLL 252 for ERa binding.
ERaSer341 phosphorylation primes SKP2 binding and ERa ubiquitylation Several substrates require phosphorylation at a 'phosphodegron' for recognition by SKP2. 15 The minimal substrate phosphorylation motif required for SKP2 binding is EXS/T. 23 ERa has two such sequences, EPS 137 and EAS 341 . The S341 site is highly conserved (see Supplementary Figure S1 ). As cyclin E-CDK2 phosphorylates EXS/T sites in other substrates, 23 we assayed its potential to phosphorylate ERa to prime SKP2 binding.
Wild-type ERa (WT-ERa) and mutant ERa proteins (S137A, S341A, S137A/S341A) were overexpressed in ERa-negative MDA-MB-231 cells. WT-ERa and the ERaS137A binding to SKP2 were similar, but ERaS341A and the double mutant, ERaS137A/S341A, both bound SKP2 poorly (Figure 3b ).
To characterize further if ERaS341 phosphorylation primes E2-stimulated ERa proteolysis, the stability of WT-ERa and the phospho-deficient ERaS341A mutant were compared by CHX chase in stably transfected MDA-MB-231 lines. E2-stimulated ERaS341A proteolysis was decreased twofold compared with WTERa ( Figure 3c , t 1/2 of 12 vs 6 h), consistent with the decrease in ERaS341A-SKP2 binding (Figure 3b ).
To test if cyclin E-CDK2 could phosphorylate the ERa EXS motif, in vitro kinase assays tested eight different ERa WT or serine to alanine EPS137 or EAS341 mutant peptides as substrates. S-to-A mutation at each putative site decreased phosphorylation of the respective peptide. The stoichiometry of phosphorylation of the two EAS 341 containing peptides supports their highest probability as substrates. Phosphorylation of both ERaEAS 341 peptides (long and short forms) by recombinant cyclin E-CDK2 was fourfold greater than of ERaEPS 137 peptides indicating that EAS 341 is preferred over EPS 137 in vitro (Figure 3d) .
Interestingly, comparison of recombinant full-length WT and mutant ERa as cyclin E-CDK2 substrates in vitro showed phosphorylation of ERaS341A was markedly reduced, while that of ERaS137A was not (Figure 3e ), supporting the importance of S341 to CDK2-dependent ERa phosphorylation. Cyclin E-CDK2 pretreatment of ERa increased in vitro ubiquitylation (Figure 3f , top) and proteasomal degradation (Figure 3f , bottom) of recombinant WT-ERa and ERaS137A, but not that of ERaS341A.
ERa S294 phosphorylation was recently reported to regulate ERa-SKP2 association. 24 Properties of full-length WT-ERa, ERaS341A and ERaS294A were compared. Both ERa mutants showed a similar ability to WT-ERa to drive luciferase reporter expression over four logs of E2 (10 À 11 to 10 À 8 M) when overexpressed in ERa-negative HeLa cells (Supplementary Figure  S2A) , indicating they can both bind ligand. SKP2 degrades and coactivates ERa to drive G1-to-S W Zhou et al WT and mutant ERa proteins were precipitated from transfected HEK 293T lines, and used as substrates in cyclin E-CDK2 assays, followed by ubiquitylation and proteasomal degradation assays. As in Figure 3e , ERa phosphorylation by cyclin E-CDK2 was significantly reduced by mutations yielding ERaS341A and ERaS294A (Supplementary Figure S2B) . In vitro, cyclin E-CDK2 pre-treatment increased WT-ERa ubiquitination by SCF SKP2 . Cyclin E-CDK2 pre-treatment did not stimulate ubiquitylation of Figure S2C) . ERaS294A ubiquitylation was similar to that of WTERa both with and without prior cyclin E-CDK2 treatment. SCF SKP2 -mediated in vitro proteolysis of WT-ERa was stimulated by cyclin E-CDK2 pre-treatment, whereas ERaS341A was unaffected by cyclin E-CDK2 and resistant to proteolysis (Supplementary Figure  S2C) . Thus, although CDK2-mediated in vitro phosphorylation of ERa is attenuated by mutations affecting both S294 and S341, the S341 site constitutes the 'phosphodegron' for estrogen-driven ERa and SKP2 association. SKP2-ERa complex formation is biphasic during estrogenstimulated cell cycle re-entry Estrogen deprivation of MCF-7 induces quiescence, and E2 repletion rapidly activates both cell cycle re-entry 4 and ERa (a) MCF-7 was stably transfected with empty vector (c) or SKP2 then E2 deprived (E2-) or treated with E2 for 2 h (E2 þ ) followed by addition of CHX and ERa assayed by western blot at intervals shown (top). Western blot shows SKP2 with anti-SKP2 or anti-Xpress-tag antibody (middle). ERa decay was assayed by densitometry, and mean data from three independent experiments performed in triplicate were plotted as semi-log values relative to ERa steady-state level at the time CHX addition. (bottom). Two hours after E2 addition, ERa has a t 1/2 of 6 h in controls, and a t 1/2 of 4.5 h in MCF-SKP2 (mean±s.e.m.). (b) MCF-7 cells were infected with scramble shRNA (c) or one of two different SKP2 shRNA lentiviri (shSKP2-1, 2). Stable lines were E2 deprived then treated with vehicle (E2-) or E2 for 2 h then CHX added and ERa assayed by western blot at intervals shown (top). ERa decay was assayed by densitometry, and data from three independent experiments performed in triplicate plotted as semi-log values as in (a). Western blot shows SKP2 knockdown (lower panel). b-Actin serves as loading control. ERa t 1/2 is 6 h in E2-stimulated controls, and t 1/ 2 ¼ 11 h with stable SKP2 knockdown (mean ± s.e.m.). (c) For ERa ubiquitylation in vitro, ERa, ATP, ubiquitin, E1 and His-hCdc34 were incubated with SCF SKP2 per Materials and methods section and ERa precipitates blotted with anti-ubiquitin. (d) In vitro degradation assay was as in (c) with the addition of 26S proteasome complex for the indicated times followed by western blot for ERa. Data from three independent experiments performed in triplicate were plotted as percent of remaining ERa protein level ( ± s.e.m.) relative to ERa protein level at the starting time. In lane 6, ERa levels were significantly lower at 1 and 2 h compared with T ¼ 0 controls two-tailed Student's t-test ( % and * signify Po0.05). or SKP2-2X LXXAA) were assayed for Xpess-SKP2-bound ERa by IP-blot. Antibody without lysate served as control. (b) Sequence alignment of EXT/S motifs from p27, p21 and ERa on top. Bold type indicates serines mutated to alanine in ERa mutants. ERa-negative MDA-MB-231 cells stably transfected with vector only (vector), WT-ERa (ERa WT) or ERa mutants (S137A, S341A or S137A-S341A) were assayed for SKP2-bound ER. Antibody without lysate served as control. (c) Stably transfected MDA-MB-231 ERa WT and ERa S341A were E2 deprived, treated with vehicle (E2-) or estradiol (E2 þ ) for 2 h then CHX added and ERa assayed by western blot at intervals shown. b-Actin serves as loading control. Densitometry and linear regression of data from three independent experiments performed in triplicate shows ERa WT has a t 1/2 of 6 h, and ERa S341A has a t 1/2 of 12 h (mean ± s.e.m.). (d) ERa WT and mutant peptides were reacted with cyclin E/CDK2 kinase in vitro. Radioactivity in ERa peptides was quantitated by liquid scintillation; data were normalized to highest read, and graphed as means ± s.e.m. from triplicate assays. Insert (right) shows control radioactivity recovered on the filter when substrate was omitted from the reaction. Significance was determined by two-tailed Student's t-test by comparing S341 containing peptides with S137 containing peptides (comparison were done for both long forms and short forms) ( % Po0.05 or %% Po0.01). (e) Recombinant FLAG-ERa WT, ERa S137A, ERa S341A and ERa S137A-S341A were used as substrate for in vitro kinase. Coomassie staining shows equal input of each purified protein. Control (c) reactions contained all reagents except substrate. Activity of recombinant ERa proteins was quantitated by liquid scintillation counting; data were normalized to highest read, and graphed as means ± s.e.m. from triplicate assays. Significance was determined using a two-tailed Student's t-test by comparing radioactivity in WT recombinant ERa protein with that in ERa mutants ( % or *Po0.05). (f ) Recombinant ERa WT, ERa S137A, ERa S341A and ERa S137A-S341A were used as substrate for in vitro ubiquitylation and degradation assays with or without cyclin E/CDK2 pre-treatment.
SKP2 degrades and coactivates ERa to drive G1-to-S W Zhou et al proteolysis. 7, 25 MCF-7 cells were synchronized in G0/G1 by 48 h E2 deprivation. Cell cycle profiles after E2 addition showed early S-phase entry by 12 h, with peak S-phase at 21 h (Figures 4a and  e) . Cellular SKP2 levels were minimal in G0/early G1, rising at the G1/S transition (Figure 4a) . Cyclin E and CDK2 protein levels were unchanged during G1-to-S phase, but T160-phosphorylated CDK2 increased 26 ( Figure 4a ) with cyclin E-CDK2 activation. Cyclin E-CDK2 activity increased by 8-12 h and peaked by 16 h, before peak S phase (Figures 4b and e) .
Despite the decline in ERa, its co-precipitation with CDK2 increased during G1 (Figures 4c and e) . Notably, although ERa levels fell and SKP2 levels increased during G1 to S phase, ERa-SKP2 binding increased in late G1, peaking after cyclin E-CDK2 activation (Figures 4b, d and e and Supplementary Figure S3B) . The kinetics of these events, graphed in Figure 4e , support a model in which activated cyclin E-CDK2 binds and phosphorylates ERa to prime its recognition by SKP2.
Recent work suggests that ERa phosphorylation at S294 by MAPK promotes SKP2 binding. 24 Estrogen rapidly activates MAPK within 5 min, with inactivation by 6 h (Figure 4f and Supplementary Figure S3A) . In early G1, SKP2 t 1/2 and levels are low 27 ( Figure 4b ). Despite low SKP2 levels, ERa-SKP2 complexes were detected 1 h after E2 (Figure 1c ), considerably before cyclin E-CDK2 activation. Comparison of early and late time points revealed two phases of ERa-SKP2 binding (Figure 4f and Supplementary Figure S3B ). Complexes were absent in estrogenstarved cells, but low ERa-SKP2 complex levels were detected within 5 min after E2 stimulation, co-incident with rapid MAPK activation, remained stable between 15 min to 6 h, then increased dramatically after cyclin E-CDK2 activation in late G1. When SKP2 levels increased, ER levels were significantly decreased, thus relative protein levels did not favor binding in late G1.
We next compared effects of CDK2 (Roscovitine) and MEK (U0126) inhibitors. Both blocked E2-stimulated G1-to-S-phase progression (Figure 4h ). U0126 abolished both the rapid E2-driven MAPK activation and early ERa-SKP2 complex assembly, whereas Roscovitine did not affect either. However, the CDK2 inhibition by Roscovitine abolished the dramatic late G1 rise in ERa-SKP2 complexes (Supplementary Figure S3B) .
MEK inhibition prevented cyclin E-CDK2 activation, arrested cell cycle progression and both early and late phases of ERa-SKP2 assembly were lost (IP-blots and quantitation shown in Figures 4f and g with greater detail in Supplementary Figure S3 ). These data suggest that both MAPK and CDK2 may promote ERa-SKP2 binding, with the former having an early role and CDK2 driving late assembly.
In E2-deprived cells, ERa is stable. 6 E2 addition rapidly (within minutes) stimulates ERa proteolysis. 25, 28 As cyclin E-CDK2 activation and SKP2 rise in late G1, SKP2 would affect a later phase of E2-activated ERa degradation. This model would predict that ERa proteolysis kinetics may differ between early and late G1. CHX chase experiments started at 3 and 12 h after estradiol addition, respectively, showed ERa t 1/2 of 6 h in early G1 and a t 1/2 of 5 h in late G1/S (Figure 4i ). This bimodal pattern with different ERa halflives early and late after estrogen stimulation, suggests early and late mechanisms govern E2-activated receptor proteolysis.
SCF
SKP2 regulates ERa target gene expression for G1/S transition and S-phase progression If SKP2 acts as both ubiquitin ligase and as coactivator for ERa, SKP2-ERa-driven gene targets would be induced late in G1, after cyclin E-CDK2 activation. To identify putative SKP2-coactivated ERa target genes whose expression increases in late G1/S, MCF-7 gene expression profiles were compared before and early (at 3, 6 h) or late (12 h) after E2 stimulation. Total RNA from triplicate samples was extracted, labeled and hybridized to Agilent wholegenome arrays representing 441 000 transcripts (Figure 5a ).
Differential expression was assessed as the average ratio between two treatment conditions, with 42-fold change with a false discovery rate o0.05. Late estrogen-activated genes were selected using a cutoff of 1.5-fold increase between 6 and 12 h. Twenty-two genes were upregulated in late G1 by this criterion (Figure 5b and Supplementary Table S1 ). Many of these are involved in the G1/S transition or mitosis (E2F-1, FBXO5/EMI1), and in DNA replication (BLM, CDC6, RFA). Over 80% of the genes we found increased by 41.5-fold between 6 and 12 h after E2 addition were also upregulated by E2 in three other publically available array databases. [29] [30] [31] Of these late E2-activated genes, several contained ERa-binding AP-1/Sp-1 sites within 10 kb of their promoter start sites and were predicted by the Hormone Receptor Target Database 32 to be ERa targets (Supplementary Table S2 ). Several also bear partial ERE consensus motifs in their promoters (Figure 5b ). Q-PCR confirmed late upregulation for two of these, E2F-1 and BLM (Figure 5d ). E2 stimulated a modest early E2F-1 induction within 3-6 h in both MCF-7 and ZR-75-1, but E2F-1 mRNA levels then rose significantly by 12 h (Figures 5d and f) .
In both MCF-7 and ZR-75-1, SKP2 knockdown delayed and attenuated peak S-phase entry (Figures 5c and e) and decreased the late induction of E2F-1 and/or BLM (Figures 5d and f) . Notably, the early E2F-1 induction by estrogen was not affected by SKP2 knockdown, but its late G1 upregulation was. Not all E2-driven genes expressed late were SKP2 regulated: the late E2-activated RAB31 induction was not affected by SKP2 knockdown. Canonical ERa target genes, such as pS2 and GREB1 were rapidly activated by E2 stimulation, but were not affected by SKP2 knockdown (Supplementary Figure S4) .
WT-SKP2 overexpressing MCF-7 showed a notable increase in late E2-mediated E2F-1 and BLM induction at 12 and 24 h after E2 addition ( Figures 5g and h) ; this was not seen in cells overexpressing the C-terminal LXXLL mutant, SKP2-L 248 QTLL 252 . SKP2-L 114 PEAA 118 did not differ from SKP2 WT in its effects on E2F-1 and BLM activation.
SKP2 binds late ERa target gene promoters E2F-1 and BLM are known to be upregulated by ERa/Sp-1 or ERa/ AP-1 binding. 33, 34 To further investigate whether SKP2 coactivates ERa at these target genes, SKP2 and ERa binding to their Sp-1/ AP-1 promoter elements was assayed by chromatin immunoprecipitation (ChIP). ERa occupied both E2F-1 (Figures 6a and b) and BLM (Figure 6c ) promoters late after E2 stimulation. Binding increased between 12 and 18 h and was inhibited by tamoxifen. In both MCF-7 and ZR-75-1, ChIP/re-IP showed late E2-stimulated E2F-1 promoter co-occupancy by ERa, SKP2, SRC-3 and RNA polymerase II that was blocked by tamoxifen pre-treatment (Figures 6a and b) . Similar findings were observed for BLM (Figure 6c) .
Finally, Xpress-WT-SKP2, but not the LXXLL mutant SKP2-L 248 QTAA 252 , showed a considerable increase in binding at E2F-1 and BLM promoters at 12 and 24 h after estrogen stimulation (Figure 6d) . Binding of the more proximal LXXLL mutant SKP2-L 114 PEAA 118 to the respective E2F-1 and BLM promoter Sp-1/AP-1 elements did not differ significantly from WT-SKP2. Taken together, these data suggest that E2F-1 and BLM are part of a subset of late-activated ERa target genes coactivated by SKP2.
DISCUSSION
As for many TFs, 14 ERa activation by ligand rapidly stimulates both its transcriptional competence and its ubiquitin-dependent degradation. 35 Although certain E3 ligases serve as ERa coactivators, 25 For cyclin E-CDK2 kinase activity, cyclin E was precipitated and reacted with histone H1 and radioactivity in substrate ( 32 P-H1) shown by autoradiography. Activity was quantitated by phospho-imager and graphed as mean % max activity ± s.e.m. from 43 assays in (e) below. (c, d) CDK2-bound ERa (c) and SKP2-bound ERa (d) assayed at intervals after E2 addition. (e) Quantitation of data from a-c above. The experiments were repeated at least three times. Data were normalized to highest read, and graphed as mean % max±s.e.m. from 43 assays. (f ) E2-deprived MCF-7 were treated with E2 for intervals shown, lysed and assayed for SKP2-bound ERa. Lanes 1 and 2 are antibody control and normal immunoglobulin G control for IP. Lower panel shows input on western blot. (g) SKP2-bound ERa was assayed at intervals after E2 addition ± pre-treatment with CDK2 inhibitor Roscovitine or MEK inhibitor U0126, and graphed as mean % max ± s.e.m. from 43 assays (see also Supplementary Figure S2) . Significance was determined using a two-tailed Student's t-test by comparing control with that from drug pre-treatment ( % Po0.05 or **Po0.01). (h) Flow cytometry (% S phase) showed cell cycle re-entry at 18 h in control but not in drug treated cells. (i) E2-deprived MCF-7 were treated with E2 for 3 or 12 h before adding CHX and harvested at various time points for ERa western blot. b-Actin serves as loading control. After 3 h of E2, ERa has a t 1/2 of 6 h, whereas after 12 h of E2, ERa has a t 1/2 of 5 h.
of ERa by cyclin E-CDK2 increases SKP2-mediated ERa ubiquitylation and proteolysis in vitro. ERa-SKP2 complexes are absent in E2-deprived cells and estrogen stimulates early rapid MAPK activation and low level ERa-SKP2 binding followed by a more dramatic rise in ERa-SKP2 binding after cyclin E-CDK2 activation in late G1. Loss of potential to phosphorylate ERa at a SKP2-binding EXS motif surrounding ERaSer341 abrogates both ERa-SKP2 binding and the priming effect of cyclin E-CDK2 on SKP2-mediated ERa proteolysis . ERa ChIP/Re-IP used SKP2, SRC3 or polymerase II (Pol II) Abs for the re-precipitation. The fractions of protein bound to the promoter at different E2 treatment intervals were compared with that of E2 depleted cells and significant differences were determined using a two-tailed Student's t-test ( % Po0.05). (c) ERa ChIP was performed at the BLM promoter. ERa ChIP/Re-IP used antibodies to SKP2, SRC3 or Pol II. The fractions of protein bound to the promoter at different E2 treatment intervals were compared with that of E2 depleted cells and significant differences were determined using a two-tailed Student's t-test ( SKP2 degrades and coactivates ERa to drive G1-to-S W Zhou et al in vitro. Expression profiling identified estrogen-induced genes that rise late, at the G1-to-S transition. Of these, E2F-1 and BLM, are identified as SKP2-dependent ERa targets, whose transactivation involves estrogen-stimulated ERa, SKP2, SRC-3 and polymerase II promoter occupancy. As E2F-1 transactivates both cyclin E and SKP2, present findings support a feed forward mechanism whereby late SKP2-dependent ERa-driven gene induction would feed forward to drive S-phase entry. Several E3 ligases have been proposed to have roles in ERa degradation including MDM2, 17 E6-AP, 16 BRCA1-BARD1 36 and cullin-based RING finger type E3 ligases, CUL4B-AhR, 37 CUL5 38 and CUL7. 24 Although multiple cullin-based RING ligases may regulate ERa in a cell-type-dependent manner, potential effects of these E3s on ERa transactivation function remained largely unknown. Our preliminary observation that Cul1-bound ERa and DN-Cul1 attenuated E2-activated ERa loss, stimulated further investigation of SCFs as ERa ubiquitin ligases. SCF SKP2 regulates degradation of CDK inhibitors, 21, 39 cyclin E 40 and factors involved in DNA replication (Cdt1), 41 and repair (BRCA2 and NBS1). 42, 43 Present work suggests a novel SKP2 function linking estrogenic ERa activation to cell cycle progression with periodic, estrogen-driven interaction between cellular SCF SKP2 and ERa as substrate in late G1. This contrasts with a recent report of estrogen-independent SKP2-mediated ERa proteolysis that involves a Cul7 complex. 24 Cell cycle progression requires successive cyclin-CDK activation. CDK2 regulates the G1/S transition. Although CDK1 can compensate genetic CDK2 loss in CDK2 À / À mice, 44 micro-injected antibodies to cyclin E or CDK2 arrest somatic cells in G1. 45, 46 In late G1 and S phases, cyclin E-CDK2 phosphorylates nuclear substrates, including the retinoblastoma protein, histone H1, CDC6 and other proteins involved in DNA replication. 19 Present findings suggest a model in which ERa phosphorylation by cyclin E-CDK2 drives activation of late ERa target genes to promote G1/S progression and beyond. Although a majority of CDK2 substrates have a S/T-P central motif, the putative CDK2 site at S341 in ERa lacks this motif. Notably, only half of identified substrates have this full consensus and at least 10% of CDK2 substrates have been shown not to be proline directed. 47 Of the non-proline directed CDK2 substrates, about half contain RXLF or K/RXLXF motifs that promote CDK2 substrate binding. Notably, the putative CDK2 phosphorylation site at ERaS341 is followed by two RXLF motifs (R 352 ELV 355 and K 401 LLF 404 ) that would promote CDK2-substrate binding. 48 Liganded ERa promotes G1 transit by cross talk between liganded ERa and Ras-Raf-MAPK 1 and by cyclin D1 induction in early G1, to activate CDK4 and CDK6, followed by cyclin E-CDK2 activation. These CDKs phosphorylate and inactivate the retinoblastoma protein, releasing activated E2F-1.
49 E2F-1 in turn transactivates cyclin E and cyclin A genes. 49 Thus, cyclin E-CDK2 creates a positive feedback loop through E2F-1, to induce further cyclin E. E2F-1 also drives SKP2 expression, 50 which further activates cyclin E-CDK2 via SKP2-mediated degradation of the CDK inhibitor, p27.
51 Cyclin E-CDK2 also phosphorylates p27 to prime its degradation by SCF SKP2 . 51 As a check on this process, SKP2 autoregulates by mediating both E2F-1 52 and cyclin E degradation. 40, 53 Present data reveal a novel mechanism of E2F-1 induction in ERa-positive breast cancer cells (Figure 7) . In hormone-sensitive tissues, liganded ERa translocates to the nucleus where cyclin E-CDK2 phosphorylates ERaS341 to prime its binding to SKP2, and transactivation of E2F-1. Increased E2F-1 expression, together with E2F-1 activation via cyclin D-and cyclin E-CDKs, would feed forward to further induce SKP2 , cyclin E, cyclin A and other E2F-1 target genes that drive S and G2/M progression. 49 Although we observed cyclin E-CDK2-mediated ERaS341 phosphorylation primes SKP2 binding, ERa ubiquitylation and degradation in vitro, Bhatt et al. 24 suggested that p38 MAPK-driven ERa phosphorylation at S294 mediates SKP2 binding and receptor proteolysis and showed ERaS294A was stable and unaffected by SKP2 overexpression. Present data allow a model in which ERa phosphorylation at S294, which is observed within 30 min after E2 addition, 54, 55 co-incident with rapid transient MAPK activation, may prime low level early ERa-SKP2 binding. Both pMAPK and early ERa-SKP2 binding were abolished by U0126, but were unaffected by the CDK2 inhibitor, Roscovitine, which did not inhibit early MAPK activation. However, since both U0126 and Roscovitine prevent G1-to-S progression, they both prevent the late, more dramatic CDK2-dependent rise in ERa-SKP2 following cyclin E-CDK2 activation. Bhatt et al. 24 showed DN-MAPK, and inhibitors of p38 MAPK and CDK2 (all of which block G1-to-S transit), all impaired the increase in ERa ubiquitylation caused by SKP2 overexpression, compatible with our data. Our observation that ERaS294A was not resistant to SCF SKP2 -mediated ubiquitylation while ERaS341A was, together with the observed priming effect of CDK2 on ERa-ubiquitylation in vitro, allow one to speculate that early S294 phosphorylation may initiate complex formation, which is then more dramatically catalyzed by sustained cyclin E-CDK2 action during late G1, to drive SKP2 coactivation of novel late ERa target genes and receptor turnover.
Cyclin E-CDK2 mediated phosphorylation of ERa leads to SKP2-dependent transcription of E2F-1, BLM and potentially other late S-phase and G2/M regulators. This is reminiscent of links between G1/S CLN-CDC28 and S-phase promoting CLB-CDC28 complexes in S. cerevisiae. In yeast, the G1 CDK complex, CLN-CDC28, phosphorylates TFs like PHO4 that activate CLB-CDC28 to drive S-phase gene expression and G2/M progression. 19 Similarly, cyclin E-CDK2-mediated activation of ERa-SKP2 would drive E2F-1 transactivation to promote S-phase entry and G2/M CDK activation. Our expression profiling identified many late E2-responsive genes upregulated between 6 and 12 h, which encode TFs governing S phase (E2F-1 and E2F-8), DNA replication (CDC6, BLM and RFC3) or mitosis (FBXO5/EMI1 and CENPQ). Notably, several contain both ERE half-sites and Sp-1/AP-1 motifs in their promoters. Of these, the Sp-1/AP-1 sites on E2F-1 and BLM promoters were shown to be hormone regulated, with late E2-driven promoter occupancy by ERa-SKP2.
Typically, E2-activated genes induced early within 1-3 h by liganded ERa, such as c-Myc , involve ERa interaction at AP-1/Sp-1 sites; 56 whereas ERE-containing genes are activated by 4-6 h. Figure 7 . Model of E2F-1 activation via classic retinoblastoma protein (pRb) pathway or via novel ERa/SCF SKP2 pathway. G1 progression is stimulated by SKP2-mediated p27 degradation, which frees cyclin E-CDK2 to phosphorylate pRB, releasing activated E2F-1. Activated cyclin E-CDK2 phosphorylates ERa, priming ERaSCF SKP2 binding and E2F1 transactivation in late G1. E2F1 induction and activation feed forward to induce further cyclin E, A and SKP2, driving late G1 and S-phase entry.
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Although most genes induced late after E2 may be upregulated secondarily by other TFs, E2F-1 and BLM appear to be induced by ERa. Whether very late-activated ERa targets, upregulated more than 12 h after E2, are regulated more often via an Sp-1/AP-1 mode, as observed for E2F-1 and BLM, or involve ERE sites warrants further investigation. The present work identifies these lateactivated genes as bona fide ERa targets and describes a novel mechanism of their periodic coactivation via SKP2. Whether this or similar mechanisms drive late activation of other hormone receptor targets will need further evaluation. Deregulation of G1-S progression is a hallmark of cancer. Aberrant CDK2 activation is frequent in human cancer. 58 That CDK2 inhibition blocks proliferation of cultured cancer cells, 45, 46 suggests that they may be 'oncogene-addicted' to CDK2. In cancers, CDK2 activation results from increased cyclin E, loss of p27 and/or SKP2 overexpression. 51 Notably, several primary breast cancer studies found a strong association between the ERanegative status and reduced CDK2 inhibitor p27 protein (Po0.0001). 51 A similar relationship was also observed for elevated SKP2 and ERa-negative status. 21, 24 Present data suggest that in ERa-positive cancers, deregulated cyclin E-CDK2 would increase estrogen sensitivity by promoting ERa-SKP2 interaction, and the expression of E2F-1 and other ERa target genes to augment mitogenic effects of estrogen.
MATERIALS AND METHODS
Cell culture and cell cycle analysis MCF-7, MDA-MB-231 and HEK 293T and derivatives were cultured as in Chu et al. 59 MCF-7 and shSKP2-MCF-7 cells were E2-depleted in improved minimum essential medium (IMEM) media with 5% charcoal-stripped fetal bovine serum for 48 h. Cell cycle entry was stimulated by E2 (10 À 8 M). Cells were BrdU pulse labeled at intervals and cell cycle analyzed by flow cytometry as in Chu et al. 59 ZR-75-1 cells were cultured as in Daly and Darbre. 60 Derivation of SKP2 overexpression and knockdown lines generated from MCF-7 including MCF-7/wtSKP2, MCF-7/SKP2 LPEAA, MCF-7/SKP2 LQTAA, MCF-7/SKP2 2X mut, MCF-7/shSKP2-1, and MCF-7/ shSKP2-2 and of MDA-MB-231 variants overexpressing ER-WT or ER mutants is described below. Roscovitine and U0126 were purchased from Cell Signaling Technology (Danvers, MA, USA).
Western blot and CHX chase
Western blot and CHX chase were as described. 28 Antibodies to ER (HC-20, F-10), CDK2 (M2), cyclin E (HE-12, HE111) and ubiquitin (P4D1), were from Santa Cruz (Santa Cruz, CA, USA); to SKP2 (8D9) and Xpress from Invitrogen (Carlsbad, CA, USA); to CUL1, SKP1 and RBX1 from Abcam (Cambridge, MA, USA); to b-actin (C-4) from Millipore (Billerica, MA, USA). The ERa t 1/2 was determined by CHX chase, with addition of 100 mg CHX considered t ¼ 0. Cells were lysed at the times indicated and ERa was blotted. For determining the ERa half-life, ERa protein was quantitated by densitometry from 3 experiments using Glyko BandScan software (version 5.0; Glyko, Hayward, CA, USA).
Immunoprecipitation/immunoblotting and immunodepletion
For immunoprecipitations, lysate was precleared with 30 ml of protein A sephorase for 2 h and then incubated with primary antibodies or normal rabbit or mouse immunoglobulin G or antibody without lysate as control (Ab) over night at 4 1C. Complexes were collected on protein A/G Sepharose (Invitrogen) and resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis followed by immunoblotting.
Immunoprecipitated cyclin E-CDK2 kinase assays
Cellular cyclin E-Cdk2 complexes were precipitated with anti-cyclin E mAb H111 (Santa Cruz) and kinase activity vs histone H1 assayed and quantitated as in Chu et al. 59 Plasmids, site-directed mutagenesis and transfection Human SKP2 vector, pcDNA4-Xpress-SKP2 is from H.K.Lin (Houston, TX, USA). Mutagenesis converting lysine 147/148, 251/252 to alanine in pcDNA4-Xpress-SKP2 used QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). MCF-7 cells were transfected with different pcDNA4-Xpress-SKP2 constructs using lipofectamine, and stable lines selected with G418. ER S137A, ER S341A and ER 2X Mut were cloned similarly and stable MDA-MB-231/ER variants generated. Lentiviral short hairpin RNA (shRNA)-mediated inhibition of SKP2 expression For lentiviral shRNA production, 293T cells were co-transfected with one of two antisense sequences of SKP2 shRNA (Open Biosystems, Huntsville, AL, USA) or green fluorescent protein control shRNA with packing plasmids (pCMV deltaVPR8.9) and envelope plasmid (pCMV VSV-G) using Lipofectamine 2000 reagent (Invitrogen) in accordance with the manufacturer's instruction. After 2 days, virus-containing media were collected, filtered and added to cell monolayers overnight then replaced with fresh growth medium and puromycin 500 ng/ml added. ShRNA sequences used are: SKP2-lentiviral shRNA-1 (5 0 -GCCTAAGCTAAATCGAGAGAA-3 0 ), SKP2-lentiviral shRNA-2 (5 0 -CCATTGTCAATACTCTCGCAA-3 0 ) and green fluorescent protein shRNA (5 0 -GCAAGCTGACCCTGAAGTTC-3 0 ).
Expression and purification of bacculoviral ERa protein and SCF SKP2 complex FLAG-tagged human ERa (or mutant) was purified from insect Sf9 cells infected by recombinant baculoviri harboring the FLAG-tagged ERa-coding sequence derived from pPK-ERa-FLAG (or pPK-ERa-FLAG(S137A, S341A or double mutant) as reported.
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SCF SKP2 complexes were purified from Sf-9 cells after co-infection with bacculovirus containing each SCF SKP2 component (pBac-His-CUL1, pBacHis-SKP1, pBac-RBX1, pBac-GST-SKP2). 21 In vitro cyclin E-CDK2 kinase assays using recombinant FLAG-ERa or cellular ERa as substrate
Recombinant glutathione S-transferase-cyclin E and CDK2 (Millipore) 5 ng was reacted with 1 pmol full-length recombinant FLAG-ERa (WT or S341A or S137A mutants) in 25 ml kinase buffer (0.1 mM ATP, 0.02 mCi/ml [g-32P]-ATP, 8 mM MOPS/NaOH pH7.0 and 0.2 mM EDTA) at 30 1C for 10 min. Control reactions contained all reagents without substrate. The reactions were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by autoradiography. Glutathione S-transferase -tagged cyclin E (87 kDa) and CDK2 (34 kDa) were readily distinguished from that of ERa protein (66 kDa). To quantitate radioactivity incorporated into ERa, reaction mixtures were dotted onto P81 filtermat, washed 3X with 75 mM phosphoric acid, then once with methanol, and radioactivity in ERa substrate was measured by liquid scintillation. The minimal radioactivity in no substrate controls was subtracted and results were graphed as mean radioactivity in substrate of 43 independent reactions ± s.e.m.
In vitro kinase assays using cellular ERa as substrate used methods as for recombinant FLAG-ERa proteins. Full-length ERa (WT or mutant ERaS341A, ERaS294A) overexpressed in HEK 293T cells were precipitated with HC-20 antibody from 1 mg cell lysate and used as substrates in cyclin E-CDK2 kinases assays. Control reactions contained all reagents without substrate. Radioactivity in ERa was quantitated and graphed as above. ERa proteins were then subjected to in vitro ubiquitylation and degradation assays. For kinase assays, reactions were stopped by adding 2X sodium dodecyl sulfate sample buffer and then resolved by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel electrophoresis, gels dried and visualized by autoradiography.
In vitro kinase assay using ERa peptides
In vitro kinase assays using ERa peptide substrate used methods as for fulllength ERa proteins. Reactions were stopped with 5 ml of 3% phosphoric acid, 10 ml aliquot dotted onto P81 filtermat, washed 3X with 75 mM phosphoric acid, once with methanol and radioactivity in ERa peptide substrate measured by liquid scintillation. Control reactions contained all reagents and kinase but no substrate. ERa peptide synthesis used Sigma PEPscreen Custom Peptide Libraries, St Louis, MO, USA. Peptides used are:
(1 
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In vitro ERa ubiquitylation and proteasomal degradation assays Ubiquitylation assays were as in Sun et al. 25 and used 40 ng each of recombinant ERa (Calbiochem, San Diego, CA, USA), ubiquitin-activating enzyme, his-tagged-Ubc H1, Cdc34, 400 ng SCF SKP2 components from bacculovirus, and an energy regenerating system (Boston Biochem, Cambridge, MA, USA) in 7.4 mM HEPES (pH 7.4), 5 mM KCl, and 1.5 mM MgCl2 reacted for 60 min at 30 1C. Reactions were diluted 10-fold in phosphate-buffered saline, and ERa precipitated, complexes were resolved, transferred to nitrocellulose. The membrane was boiled for 10 min. Ubiquitinated ERa was detected by immunoblotting with antiubiquitin Ab as in Chu et al. 28 ERa degradation was assayed as above, with modifications: 50 nM 26S proteasome fraction (Boston Biochem) was added for 1-2 h at 30 1C before ERa western blot. 28 Luciferase reporter gene assays and transfections For reporter gene assays, 2 mg GREB-ERE1-luc and 100 ng pcDNA3-ERa (WT or Mut) or control vectors were transfected and reactions carried out as described. 62 Gene expression array analyses RNA was extracted with RNeasy mini kit (Qiagen, Valencia, CA, USA) and processed for Agilent Whole-Genome Oligo microarrays (Agilent, Santa Clara, CA, USA) as per the manufacturer. Arrays were scanned with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). Raw data were analyzed with GenePix Pro 6.1 (Molecular Devices). Two biologic replicates were used for each treatment. Differential expression and false discovery rate were assessed by linear model and empirical Bayes moderated F statistics.
RNA extraction and gene expression quantification MCF-7 or MCF-7/ShSKP2 cells were E2-depleted for 2 days before adding 10 nM b-estradiol or 10 mM tamoxifen plus estradiol for 6 or 12 h. Total RNA was isolated using TRIzol (Invitrogen). cDNA synthesis used 1 mg total RNA and iScriptcDNA kit (Bio-Rad, Hercules, CA, USA) and gene expression was quantified by RT-qPCR as described. 62 
Chromatin immunoprecipitation
The ChIP experiments were performed as described. 25 ChIP/Re-IP (sequential ChIP or reChIP)
ChIP/Re-IPs were carried out as described. 62 Bead eluates from the first immunoprecipitation were incubated with 10 mM DTT at 37 1C for 30 min and diluted 1:50 in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl at pH 8.1) followed by a second round of immunoprecipitation.
Statistical analysis
All experiments (in cells and in vitro assays) were done at least in triplicate. Data are presented as mean±s.e.m. as percentage of control or absolute values. The values obtained for WT and mutant proteins for different parameters studied were compared by two-tailed Student's t-test. P-values o0.05 or 0.01 were designated with one or two asterisks, respectively.
